Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.41 |
| ▸ | CDC25B | P30305 | 4/20 | 0.41 |
| ▸ | ACP1 | P24666 | 3/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940256 | 0.86 | MAOA (0.35) | PTPN1CDC25BACP1HPSEMAPT | |
| SCHEMBL18919598 | 0.81 | PTPN1 (0.48) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL18919570 | 0.81 | PTPN1 (0.48) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL18919576 | 0.81 | PTPN1 (0.48) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL18919577 | 0.81 | PTPN1 (0.48) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL18919583 | 0.81 | PTPN1 (0.48) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL18919596 | 0.81 | PTPN1 (0.48) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL18919594 | 0.76 | PTPN1 (0.51) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL18919575 | 0.76 | PTPN1 (0.51) | CYP1A2PTPN1CDC25BACP1HPSE | |
| SCHEMBL21555848 | 0.76 | PTPN1 (0.54) | CYP1A2PTPN1CDC25BACP1HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933048-B2 | Compounds and methods of treating bacterial infections | ULTUPHARMA AB (SE) | 2021-03-02 | — | — | US | disclosed |
| US-20200138777-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ULTUPHARMA AB (SE) | 2020-05-07 | — | — | US | disclosed |
| US-10471043-B2 | Compounds and methods of treating bacterial infections | ULTUPHARMA AB (SE) | 2019-11-12 | — | — | US | disclosed |
| US-20180360802-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ULTUPHARMA AB (SE) | 2018-12-20 | — | — | US | disclosed |
| EP-3383857-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | Ultupharma AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095319-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ULTUPHARMA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360802-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ELANE, TNF, IL1B | CYP1A2 476/4885PTPN1 3045/4885CDC25B 2318/4885 |
| US-10471043-B2 | Compounds and methods of treating bacterial infections | ELANE, TNF, IL1B | CYP1A2 476/4885PTPN1 3045/4885CDC25B 2318/4885 |
| US-10933048-B2 | Compounds and methods of treating bacterial infections | ELANE, TNF, NISCH | CYP1A2 470/4885PTPN1 3158/4885CDC25B 2547/4885 |
| US-20200138777-A1 | COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS | ELANE, TNF, NISCH | CYP1A2 470/4885PTPN1 3158/4885CDC25B 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.